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Abstract
The blood–brain barrier (BBB) describes the unique
properties of endothelial cells (ECs) that line the central
nervous system (CNS) microvasculature. The BBB
supports CNS homeostasis via EC-associated transport
of ions, nutrients, proteins and waste products between
the brain and blood. These transport mechanisms also
serve as physiological barriers to pathogens, toxins and
xenobiotics to prevent them from contacting neural
tissue. The mechanisms that govern BBB permeability
pose a challenge to drug design for CNS disorders,
including pain, but can be exploited to limit the
effects of a drug to the periphery, as in the design of
the peripherally acting μ-opioid receptor antagonists
(PAMORAs) used to treat opioid-induced constipation.
Here, we describe BBB physiology, drug properties that
affect BBB penetrance and how data from randomized
clinical trials of PAMORAs improve our understanding of
BBB permeability.

Introduction

Maintenance of the central nervous system (CNS)
environment is important for its function and is
accomplished via three protective layers that partition the blood from neural tissue. The choroid
plexus epithelium forms the blood–cerebral spinal
fluid (CSF) barrier by secreting CSF into the cerebral ventricles, while the arachnoid epithelium
separates the blood from the subarachnoid CSF.1–3
The blood–brain barrier (BBB) is the third structure that separates the blood and neural tissue, and
refers to the unique properties of the endothelial
cells (ECs) that line the microvasculature of the
CNS.4 Here, we describe contributions of the BBB
to CNS homeostasis, particularly its differential
permeability to drugs and other substances. We
discuss the pharmacology of peripherally acting
μ-opioid receptor antagonists (PAMORAs), whose
design capitalizes on this differential permeability.

Physiology of the BBB
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Blood vessels are composed of ECs and mural cells
(ie, vascular smooth muscle cells and pericytes;
figure 1A). The diverse functions of the BBB are
mediated primarily by ECs, which form the walls
of capillaries and have unique properties compared
with ECs in other tissues.4–11 ECs of the BBB have a
greater concentration of mitochondria, which may
be related to the energy required to maintain ion
gradients necessary for transport functions.12 ECs

of the BBB also have fewer pinocytotic vessels than
ECs found elsewhere, which results in a low level
of passive solute movement out of the bloodstream
and into the interstitial fluid.9 Finally, very low
levels of leukocyte adhesion molecules in ECs of
the BBB restrict inflammatory immune cells from
entering the CNS.4
ECs of the BBB rely on tight junctions (TJs)
and an assortment of transport proteins to
control movement of substrates into and out of
the capillary lumen.4 6–8 10 11 TJs are multiprotein
complexes that connect neighboring ECs via their
lateral membranes. They consist of transmembrane proteins of the claudin and occludin families.
Protein–protein interactions within and between
cells create the functional core of the TJ, which has
a central pore of a few nanometers. The TJ pore
will allow transport of some small molecules, but
paracellular transport between ECs is generally
constrained. The core proteins of the TJ associate
associated cytoskeletal proteins
with membrane-
and adaptor proteins that may regulate TJ stability
and permeability.4 TJs are stabilized by the glia
limitans, a basement membrane formed by astrocytic end-feet, and by astrocyte-mediated signaling
to ECs.2 4 Astrocytes also contribute to BBB health
by metabolizing drugs or other toxic compounds
that leave the ECs.13
While TJs regulate paracellular movement
between blood and brain, ECs are equipped with
efflux pumps and solute carrier transporters that
mediate transcellular passage (figure 1B). Because
TJs create well-
separated luminal and abluminal
domains, the directionality of transcellular movement for many substances is determined by the
domain in which the transporter is located.14
Efflux pumps in the luminal membrane of the ECs
move many small lipophilic molecules out of the
EC cytoplasm into the blood, thus limiting their
passive diffusion into the CNS. Among the best-
characterized efflux pumps are members of the
ATP-
binding cassette (ABC) transporter family:
the P-glycoprotein transporter (P-gp),15 multidrug
resistance-associated proteins (MRP),16 and breast
cancer resistance protein.17 18 Solute carrier transporters deliver glucose, large amino acids, and
other nutrients across the EC from blood to brain,
and eliminate metabolic waste products, glutamate,
and toxins via transport from brain to blood.19 20
Receptor-
mediated transcytosis is another means
by which proteins such as insulin are moved across
ECs of the BBB.19
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Figure 1 Cellular and structural components of the blood–brain
barrier. (A) A single layer of ECs line the capillaries of the brain’s
vasculature. ECs are connected by a network of tight junctions
that inhibit paracellular transport. Pericytes and astrocytes provide
mechanical and functional support to the BBB by ensheathing ECs
at the abluminal walls. (B) Transcellular transport of nutrients and
waste is mediated by solute carrier transporters. ABC transporter
is an efflux pump that pumps drugs from ECs to blood. Receptor-
mediated transcytosis mediates transport of macromolecules such
as insulin across the BBB. Adapted from Ohtsuki et al.19 Quantitative
targeted proteomics for understanding the blood-brain barrier: towards
pharmacoproteomics. Expert Rev Proteomics. 2014;11:303–313.
Reprinted by permssion of the publisher (Taylor & Francis, Ltd, http://
www.tandfonline.com). ABC, ATP-binding cassette; BBB, blood–brain
barrier; EC, endothelial cell; SLC, solute carrier.
Similar to astrocytes, pericytes provide mechanical and functional support to the BBB by ensheathing ECs at the abluminal
wall within the basement membrane.4 21 Pericytes form peg–
socket contacts with ECs that allow for the exchange of ions,
metabolites, second messengers, and ribonucleic acids between
the 2 cell types.21 Evidence suggests that pericytes aid BBB
stability via their roles in angiogenesis, deposition of extracellular matrix, and blood flow response to neural activity.4 21
Coordinated paracrine interactions between ECs and the pericytes, astrocytes, microglia and neurons that surround them
form the ‘neurovascular unit’, whose disruption accompanies
cerebrovascular disease.22

Determinants of BBB permeability

To ensure proper function and maintain the homeostatic environment of neural tissue, the BBB must closely regulate entry
to and exit from the CNS. This includes not only endogenous molecules such as peptides, glucose and other nutrients,

and waste products, but also therapeutic medications. Studies
of drug databases indicate that only ~10% of drugs are CNS
active.23 The BBB maintains its highly restrictive nature via
passive and active mechanisms. Drugs that successfully use
passive diffusion to traverse the lipid bilayer of the BBB fulfill
several criteria related to their intrinsic and biochemical properties.23–28 One of the intrinsic properties governing permeability
is molecular weight. Molecules that weigh more than 400 Da are
generally not able to access the brain by crossing the BBB,23 29
although some larger molecules in the range of 500–600 Da are
not excluded.25 30 Another determinant of permeability is molecular volume, which affects permeability in a non-linear manner.
Fisher et al found a 100-fold decrease in penetration between
molecules with volumes of 100 Å vs 50 Å.23 31 A compound’s
hydrophilicity is the third major determinant of permeability.
Water-insolvent substances that form seven or fewer bonds with
water are thought to be able to diffuse through the lipid bilayers
of ECs to reach the brain.23 32–34
While lipid insolubility prevents many drugs from reaching the
brain via passive diffusion, active transport by the BBB’s efflux
pumps is equally important to maintain the brain’s integrity. The
P-gp transporter is characterized by a broad substrate specificity
that is made possible by aromatic, polar, and non-polar residues
within the substrate binding domains.35 The presence of multiple
substrate binding sites that are both overlapping and nonoverlapping ensures that P-
gp transporters at the BBB function
efficiently without reaching saturation.28 36 37 Most substrates
that interact with P-gp are weakly amphipathic and relatively
hydrophobic, and are able to enter cells through passive diffusion across the cellular membrane.38 P-gp intercepts substrates
within the membrane before they enter the cytosol and pumps
them into the extracellular space via an energy-dependent transport cycle driven by ATP hydrolysis.38 39 P-gp can thus prevent
diffusion of drugs to the brain and, more globally, can alter the
clinical efficacy of the drugs it interacts with by altering their
absorption and tissue distribution. Additionally, for drugs that
are substrates of P-gp and rely on the interaction with P-gp for
exclusion from the brain, exposure to P-gp inhibitors or conditions that cause P-gp deficiency can allow increased entry into
the brain.
Unlike drug–receptor interactions, interactions between a
drug and the BBB involve multiple components that contribute
positively or negatively to its permeability. As discussed previously, the impact of the EC membrane varies with the degree of
lipophilicity of the drug, being negative or positive, while the
ABC efflux transporters have a negative effect. Besides these,
the many solute carrier proteins present at the BBB will increase
the permeability of any drug that can bind to them.14 Because
a drug’s permeability profile is influenced by multiple components, subtle changes in structure can yield substantial changes in
permeability, and drugs with similar functions do not penetrate
the BBB equally. The comparison of morphine and codeine is
an example of how the BBB shows differential permeability to
structurally similar drugs. Although codeine might be expected
to display a poorer permeability profile than morphine because
of the methyl side chain, it penetrates the brain much more
quickly (single-pass clearance of drug as a percentage of a simultaneously injected tritiated water internal standard: morphine,
2.6%±0.2%; codeine, 26.0%±2.0%).40–42 BBB penetrance of
morphine and its active metabolites is governed by all three
factors discussed here.43 Morphine is able to diffuse through
the EC membrane, and it also reaches the brain via active transport; however, it is subject to efflux via MRP and P-gp.44–49 In
contrast, codeine is not a substrate for MRP or P-gp and easily
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Table 1 Summary of permeability profiles for currently marketed
opioid receptor agonists and antagonists
Degree of BBB
penetrance*

Structural
class†

Mechanism of restriction or
transport

 Hydrocodone

Complete

1

Diffusion48

 Oxycodone

Complete

1

Carrier-mediated influx47 122

 Alfentanil

Partial

2

P-gp-mediated efflux47

 Fentanyl

Partial

2

P-gp-mediated efflux47

 Meperidine

Partial

2

P-gp-mediated efflux47

 Methadone

Partial

3

P-gp-mediated efflux47

 Sufentanil

Complete

2

Diffusion48

Generic drug name
Opioid receptor agonists
Semisynthetic

Synthetic

Non-synthetic
 Buprenorphine

Partial

1

P-gp-mediated efflux47

 Butorphanol

Complete

1

Diffusion47

 Codeine

Complete

1

Diffusion48

 Hydromorphone

Partial

1

P-gp-mediated efflux123

 Morphine

Partial

1

Active influx, MRP-mediated and
P-gp-mediated efflux43 47

 Oxymorphone

Partial

1

MRP-mediated efflux47

 Tramadol

Complete

2

Carrier-mediated influx124

Opioid receptor antagonists
 Alvimopan

None

3

N-substituted side chain and
zwitterion90 117

 Methylnaltrexone

None

1

N-methyl quaternary amine87

 Naldemedine

None

1

Side chain89

 Naloxegol

None

1

PEG-ylated88

 Naloxone

Complete

1

Carrier-mediated influx125

 Naltrexone

Complete

1

Diffusion47

1

P-gp-mediated efflux126

Opioid receptor agonists–antagonists
 Nalbuphine

Partial

*Degree of penetrance was estimated as follows: complete, substrate for carrier-mediated influx and/
or not a substrate for MRP-mediated or P-gp-mediated efflux; partial, substrate for MRP-mediated or
P-gp-mediated efflux but not a substrate for carrier-mediated influx; none, substrate for MRP-mediated
or P-gp-mediated efflux and/or demonstrated lack of transport across the blood–brain barrier.
†Chemical structure class: 1, class 1, 4,5-epoxymorphinan ring; 2, class 2, phenylpiperidines; 3, class 3,
diphenylheptylamines. Adapted from Drewes et al, 2014.127
BBB, blood–brain barrier; MRP, multidrug resistance-associated protein; PEG, polyethylene glycol; P-gp,
P-glycoprotein.

diffuses across the BBB.48–50 Table 1 presents a summary of the
permeability profiles for morphine, codeine and other currently
marketed opioid receptor agonists and antagonists.

Causes of BBB dysfunction
When the BBB is compromised by stroke, total brain injury
(TBI), or normal aging, patterns of BBB permeability are altered.
Cerebral damage from ischemic stroke is generated immediately
after the event and further develops over the next few days. This
biphasic nature of injury, which can depend on the degree of
hypoxia, occurs not only in the grey and white matter but also
at the BBB. Studies in animal models suggest that as early as a
few hours after a stroke, the permeability of the BBB increases.
Further changes in permeability are detected days later.4 51 52
The response of the BBB to TBI has several similarities to the
response to stroke. First, the timeline of response is biphasic,
with the earliest changes observed in hours, and delayed-onset
disruptions in permeability over days.53–58 Second, the abnormalities that are observed are similar, with upregulation of
transcytosis.59 60 However, TBI results in extensive physical
disruption of the vasculature, as some studies have reported
localized swelling or constriction, ectasia, and membrane thickening of both capillaries and larger vessels.54 55
Aging, unlike stroke and TBI, results in uniform changes
in the BBB across brain regions. Age-related BBB dysfunction
is compounded by diminished function of the choroid plexus,
which produces less CSF and transports less materials out of
the ventricles.61–63 In the cerebrovasculature, blood flow and
blood volume, and the corresponding level of oxygenation,
are diminished in brains of older versus younger persons,64
and some studies have reported changes in capillary structure
and density.65 The ECs of older individuals show alterations in
their most highly specialized adaptations. These changes include
reduced EC mitochondrial density, reduced capacity to transport waste from brain to blood, accumulation of extracellular
matrix components and stiffening of the vessel wall, and loosening of TJs. Furthermore, a loss of pericytes compromises BBB
integrity and causes hypoperfusion and secondary neurodegeneration.66 As a result, the aged have a generally leaky BBB, with
increased permeability to many substances. Recent studies in
humans and in animal models have reported decreased expression of P-gp as a result of aging.67 68 Therefore, a heightened
response to many opioid medications would most likely be
observed in both healthy and infirm older people. These results
could potentially affect the tissue distribution of drugs such as
PAMORAs that rely, at least partially, on P-gp activity to restrict
its diffusion to the brain. Potential effects of aging and other

Figure 2 Mechanism of peripherally acting µ-opioid receptor antagonists.69 Reprinted from The Lancet, 373, Becker G, Blum HE, Novel opioid
antagonists for opioid-induced bowel dysfunction and postoperative ileus, 1198–1206, Copyright 2009, with permission from Elsevier.
CNS, central nervous system.
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causes of BBB compromise on CNS exposure to PAMORAs have
not been extensively explored to date but are currently under
investigation.

Peripheral opioid antagonism

One of the advantages of a highly impermeable BBB is that it can
be exploited to limit the activity of a drug to the periphery. This
strategy was used to develop PAMORAs,69 which are prescribed
primarily for opioid-induced constipation (OIC). OIC frequently
occurs with opioid use and is caused by activation of opioid
receptors in the gastrointestinal tract. Signaling from μ-opioid
receptors in the mucosal epithelium results in inhibition of
neurons of the myenteric plexus, a key regulator of gastrointestinal motility (figure 2).69–75 Although many patients develop
tolerance to opioid analgesia and require increasing doses for
pain relief, little tolerance to OIC develops over time.76
While laxatives are often the first treatment option for OIC,
they frequently yield complications and poor outcomes.77–79
OIC can be also improved by use of opioid antagonists such as
naloxone80 81; however, naloxone crosses the BBB and decreases
opioid analgesia.72 82–84 PAMORAs are able to reduce the symptoms of OIC while maintaining the efficacy of opioid agonists in
the CNS.73 76 85 86 Three PAMORAs have been developed to treat
OIC: methylnaltrexone (Relistor),87 naloxegol (Movantik),88
and naldemedine (Symproic).89 A fourth PAMORA, alvimopan
(Entereg), is indicated to accelerate the time to upper and lower
gastrointestinal recovery following surgeries that include partial
bowel resection with primary anastomosis.90 These PAMORAs
exhibit distinct clinical profiles and employ different mechanisms that restrict their movement across the BBB. The chemical
structures of each PAMORA, as well as the chemical structures
for morphine, codeine and naloxone, for reference, are depicted
in figure 3. Comparison of efficacy among the PAMORAs is
difficult because clinical outcomes were not the same in all trials.
However, there are several publications that have reviewed the
efficacy and safety of this class.73 91–94
One of the first PAMORAs to be developed was methylnaltrexone. As the name suggests, this drug is a modified form of
naltrexone, with a methyl group added to the compound’s sole
nitrogen. Because the resulting quaternary amine on methylnaltrexone is too polar to cross the BBB, exposure is predicted to
be limited to peripheral receptors, including those in the gastrointestinal tract.87 95–97 Methylnaltrexone and its metabolites are
not substrates for P-gp.
Methylnaltrexone was approved by the US Food and Drug
Administration (FDA) in 2008 as an injection, and in 2016 as a
tablet formulation. Both formulations are approved to treat OIC
in adults with chronic non-cancer pain (CNCP). The injectable
form is additionally approved for the treatment of OIC in adults
with advanced illnesses or pain caused by active cancer who
require opioid dosage escalation for palliative care.87 Multiple
clinical trials conducted over the past 10 years have examined
the maintenance of analgesia and the degree of withdrawal
among patients taking methylnaltrexone for OIC,98–102 and these
endpoints are key in vivo indicators of the ability of the BBB to
restrict entry of methylnaltrexone. Two of these trials, reported
by Webster et al in 2015 and Webster and Israel in 2018, examined analgesia and withdrawal by assessing the patients’ median
morphine equivalent dose (MED) in addition to their pain intensity and symptoms of withdrawal as measured by the Subjective
Opioid Withdrawal Scale and/or the Objective Opioid Withdrawal Scale. For patients receiving a 150, 300, or 400 mg oral
dose of methylnaltrexone QD, the mean MED remained stable

Figure 3 Chemical structures of (A) morphine, (B) codeine, (C)
naloxone, (D) methylnaltrexone, (E) naloxegol, (F) naldemedine, and (G)
alvimopan.
throughout 4 weeks of QD dosing and 8 weeks of as-needed
(PRN) dosing.98 Among patients who received a 12 mg subcutaneous dose QD or QOD during 48 weeks of open-label treatment, the median daily MED also showed little variation (12 mg
QD range: 150.0–180.0 mg/day; 12 mg QOD range: 144.0–
162.6 mg/day).99 The authors also found no statistically significant difference in scores for pain intensity or withdrawal after 2
or 4 weeks of treatment with either the oral or injectable formulation.98 99 Two additional randomized methylnaltrexone trials
examined analgesia and withdrawal by assessing the patients’
pain intensity and symptoms of withdrawal as measured by the
modified Himmelsbach Scale.101 102 In both studies, patients with
advanced illnesses and OIC received subcutaneous methylnaltrexone or placebo. During the double-blind phase of the study
by Slatkin et al, patients received a single subcutaneous dose of
0.15 mg/kg methylnaltrexone, 0.30 mg/kg methylnaltrexone,
or placebo.101 In the study by Thomas et al, patients received
subcutaneous methylnaltrexone 0.15 mg/kg or placebo every
other day for 2 weeks.102 No significant changes from baseline in pain scores or modified Himmelsbach scale scores were
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demonstrated at any time point in either study. Similar results
have been observed in earlier trials of methylnaltrexone administered intravenously at doses of up to 24 mg every 6 hours103 and
0.3 mg/kg every 6 hours.104 Even with the high intravenous doses
administered in these trials, signs of opioid withdrawal103 and
pain intensity104 were similar to placebo.
The FDA approved another PAMORA derived from naltrexone.
Naldemedine, approved in 2017, consists of a naltrexone backbone with a large steric side chain added at the ketone group. The
side chain renders naldemedine highly polar, and with a molecular
weight of 742.84 Da, it is unlikely to cross the BBB.89 105 Unlike
methylnaltrexone, naldemedine is a substrate for P-gp.87 89 In pharmacokinetic studies, a single dose of the P-gp inhibitor cyclosporine resulted in mild increases in naldemedine Cmax and area under
the plasma concentration time curve (AUC) (1.45-fold increase and
1.78-fold increase, respectively).89 A recent animal study suggested
gp, it is primarily
that while naldemedine is a substrate for P-
excluded from the brain due to its limited ability to cross the BBB
rather than efflux by P-gp.106
Oral naldemedine is indicated only for patients with OIC and
CNCP.89 The evidence for naldemedine’s lack of central penetration was gathered from four clinical trials.107–110 The COMPOSE
trials were phase III trials evaluating 0.2 mg daily naldemedine
over 2 weeks of randomized treatment (COMPOSE-4), 12 weeks
of randomized (COMPOSE-1 and COMPOSE-2) or open-label
treatment (COMPOSE-5), or 52 weeks of randomized treatment
(COMPOSE-3).108 109 111 All of the COMPOSE trials assessed
withdrawal and the maintenance of analgesia. Over 12 weeks
of treatment, scores on the Clinical Opioid Withdrawal Scale
(possible scores, 0–48) showed little variation and were generally less than 1.0, with no statistically significant between-group
differences in COMPOSE-1, COMPOSE-2, and COMPOSE-5.
Scores on the pain numerical rating scale and the total weekly
opioid dose (assessed in COMPOSE-1 and COMPOSE-2) were
also similar.108 111 A 4-week randomized study by Webster et al
confirmed that patients receiving naldemedine had levels of pain
and withdrawal that were similar to those receiving placebo.110
The results of the COMPOSE-3 study also demonstrated that
long-term use of naldemedine did not result in opioid withdrawal or decreased analgesia.109
Prior to approval of naldemedine in 2017, the FDA approved a
PAMORA derived from naloxone. Naloxegol, approved in 2014,
differs from naloxone by the addition of a PEG side chain.88 Like
naldemedine, naloxegol is thought to be restricted from crossing the
BBB because of its size (742 Da), its polar nature, and the activity of
P-gp.88 Also like naldemedine, the drug’s pharmacokinetics can be
influenced by treatment with P-gp inhibitors; when coadministered
with the strong P-gp inhibitor ketoconazole, naloxegol Cmax and
AUC increased 9.6-fold and 12.8-fold, respectively. Coadministration with the weak P-gp inhibitor quinidine increased naloxegol
Cmax and AUC 2.5-fold and 1.4-fold, respectively.88 Naloxegol is
manufactured as a tablet, with a dosage of 12.5 or 25 mg QD indicated for patients with OIC and chronic pain.88 Evidence of the
lack of CNS penetration of naloxegol has been generated by clinical studies in patients with OIC and in healthy volunteers.112–116
A crossover, ascending dose study of naloxegol, conducted by
Eldon et al, determined the pharmacokinetic and clinical properties of 8–1000 mg of daily naloxegol in healthy adult men. The
authors reported that pupillary miosis, a readout of centrally
acting morphine, was intact at doses up to 125 mg.112 Naloxegol’s
performance in patients with OIC and chronic pain was evaluated in the phase III KODIAC trials (KODIAC-04, KODIAC-05,
KODIAC-07, and KODIAC-08).113–116 Patients enrolled in two
12-week randomized studies (KODIAC-04 and KODIAC-05)115
692

and one 12-week randomized extension study (KODIAC-07)116
who received either daily placebo, 12.5 mg naloxegol, or 25 mg
naloxegol experienced statistically similar levels of both worst
and average pain and showed similar patterns of their daily doses
of opioid medications.113 115 116 The percentages of patients who
experienced no change in symptoms of withdrawal were similar
among the treatment groups (72%–85%), and increased to
>91% for all groups in the extension study.113 116 In the 52-week
KODIAC-08 trial, the only one to compare naloxegol (25 mg QD)
to an investigator-chosen laxative regimen, patients also reported
similar levels of pain and daily opioid doses.114 However, it has
been reported that a higher frequency of gastrointestinal adverse
events potentially related to opioid withdrawal were observed in
naloxegol-
treated patients receiving methadone compared with
other opioids for pain management.88 Additionally, possible opioid
withdrawal, defined as at least three adverse reactions potentially
related to opioid withdrawal that occurred on the same day and
were not all related to the gastrointestinal system, was noted in 3%
of patients who received naloxegol 25 mg vs 1% of patients who
received naloxegol 12.5 mg and <1% of patients who received
placebo in two studies regardless of maintenance opioid treatment.88 Collectively, the data indicate that the BBB functions as
it should when naltrexone-based or naloxone-based PAMORAs
are prescribed to patients with advanced illness or chronic pain.
However, the package inserts for all of these opioid antagonists
warn of complications of withdrawal among those with a leaky
BBB.87–89
Alvimopan was approved in 2008 as a 12 mg capsule and is
indicated for short-term, in-hospital use to accelerate gastrointestinal recovery after surgical bowel resection with primary anastomosis.90 Like other PAMORAs, it displays a highly preferential
distribution to peripheral opioid receptors.117 The BBB restricts
passage of alvimopan because an N-substituted side chain introduces a zwitterion, which renders the molecule large and highly
lipophobic.90 117 In vitro studies suggest that alvimopan and its
metabolite are substrates for P-gp; however, coadministration of
mild-to-moderate P-gp inhibitors has not been demonstrated to
influence alvimopan pharmacokinetic parameters, and clinical
studies examining coadministration of a strong P-gp inhibitor
have not been conducted.90Alvimopan is associated with a risk
evaluation and mitigation strategy because patients in a 12-month
trial of 0.5 mg two times per day alvimopan experienced a higher
rate of myocardial infarction than did those in placebo groups.90
Although several phase III trials were undertaken to examine
alvimopan’s effectiveness to treat OIC,118 development for OIC
was discontinued due to a lack of consistent efficacy data among
patients with chronic pain.76 119–121

Conclusion
The selective permeability of the BBB is integral to the maintenance of CNS homeostasis. Although the permeability of
the BBB is resistant to manipulation, it can be used as a tool to
restrict the activity of a drug to the periphery. The development
of PAMORAs to treat OIC illustrates the success of this approach,
which has tremendous implications for drug design. However,
the potential of a permeability-driven approach can only be realized when we have a thorough understanding of how the BBB is
disrupted in the most common neurological conditions.
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